ABSTRACT
Background Although several studies have reported the impact of fears relating to COVID-19 on several chronic illness populations, there are few studies focused on gastrointestinal (GI) conditions. The aim was to compare how fear of COVID-19 is manifested in people living with Inflammatory Bowel Disease (IBD) compared to other GI conditions across different demographic backgrounds (employment status, education level and country of residence) using a large international sample. Method Participants with a GI condition (≥18years of age) were recruited from 22 countries through a web-based questionnaire. Demographic, clinical, and psychosocial information was collected in relation to the COVID-19 pandemic. An adaptation of the scale developed for IBD by Trindade & Ferreira (2020, Figure 1) measuring fear of COVID-19 (FoC;original items 1-9) and GI specific fear of COVID-19 (GI-FoC;new items 10-14) was used. Oneway ANOVA or x2 test was chosen as appropriate. Results In 831 participants (312 IBD), there were no significant differences in FoC between IBD and other GI conditions;whilst significant increases in GI-FoC were found in IBD respondents (mean [SD]: 13.5 [5.5] vs. 10.9 [5.0], p<0.01). The greatest fears of IBD respondents were: their condition would get worse;impact on access to medical support;being at increased risk of getting COVID-19;and being at increased risk of death if they got COVID-19. Having an unclassifiable employment status, e.g. redundancy, (mean [SD], unclassifiable: 33.3 [9.3], employed/students: 25.9 [8.3], unemployed: 28.6 [11.5], retired/ home duties: 27.2 [8.6], p<0.01) impacted on IBD respondents having FoC (and near significant GI-FoC [p=0.051]). Those individuals were more afraid of contracting COVID-19 or having contact with other people. Participants living in a rural setting had significantly more FoC and GI-FoC (mean [SD], rural setting: 28.9 [9.9] & 13.3 [5.5], regional setting: 25.5 [7.9] & 12.9 [5.0], metropolitan setting: 27.0 [8.9] & 13.3 [5.5], p=0.04 & 0.03, respectively). These participants were more afraid of having contact with other people, going outside, and believed that they are more likely to get COVID-19 and more likely to die if they got COVID-19 due to their IBD. There were no differences in FoC and GI-FoC by education levels. However, participants with higher education were less afraid of dying from COVID-19 (question 9, p<0.01). Conclusion Respondents with IBD are more afraid of the consequences of COVID-19 due to their disease compared to other GI diseases;especially, persons with undefinable employment status or persons living in a rural setting. Persons with higher education were less afraid of dying from COVID-19. These findings should be taken into consideration to personalize the support health care providers can offer in mitigating fear related to COVID-19 in IBD patients.(Table Presented)
ABSTRACT
Background: Cases of Coronavirus disease 2019 (COVID-19) have emerged in discrete waves across different regions in the world. We explored temporal trends in the reporting of COVID-19 in patients with inflammatory bowel disease (IBD), in a large global database. Methods: The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry to study the character-istics and outcomes of patients with IBD diagnosed with COVID-19. Joinpoint regression models calculated the average percent change (APC) with 95% confidence intervals (CI) in weekly reported cases of COVID-19 in patients in the registry stratified by geographic regions (Asia, Europe, Latin America, and North America) during two time periods: March 22 to September 12 and September 13 to November 14, 2020. We also determined the APC in US regions (Midwest, Northeast, South and West) during the two time periods. Results: Across 63 countries and dependencies, 3,195 cases of COVID-19 in people with IBD were reported over an 8-month period. Overall, COVID-19 reporting steadily decreased throughout the world by 4.5% per week (95% CI: −5.7, −3.2) from March 22 to September 12, 2020 but then steadily climbed by 12.4% per week (95% CI: 6.8, 18.3) from September 13 to November 14, 2020. After stratification by geographic region, weekly reporting declined before September 13 in North America (APC = −2.0%;95% CI: −3.7, −0.4), Asia (APC =− 4.4%;95% CI: −7.8, −0.9), and Europe (APC = −8.6%;95% CI: −10.6, −6.6), but escalated in Latin America (APC = 3.4%;95% CI: 0.7, 6.1) (Figure 1). After September 12, the rate of weekly cases decreased in Latin America (APC = −19.0%;95% CI: −33.3, −1.7) and Asia (APC = −19.3%;95% CI: −34.6, −0.5), while increased in North America (APC = 10.7%;95% CI: 4.3, 17.4) and Europe (APC = 28.0%;95% CI: 17.3, 39.6) (Figure 1). Within the US, temporal trends differed by region: Midwest (stable APC: −0.8%;95% CI: −3.5, 1.9 then increase APC: 27.3%;95%: 16.1, 39.6), Northeast (decrease APC: −9.1%;95% CI:− 11.8, −6.2 then stable APC: 2.4%;95% CI: −9.9, 16.5), South (increase APC: 5.3%;95%CI: 2.5, 8.3 then decrease APC: −12.0;95% CI: −18.4, −5.0), and West (stable APC: 0.2%;95% CI: −3.0, 3.5 then stable APC: 9.0%;95% CI: −13.8, 37.9) (Figure 2). Conclusion: COVID-19 reporting to SECURE-IBD declined steadily during the first wave of the pandemic throughout the world except Latin America. Starting in September, reports to SECURE-IBD rose in both Europe and North America, consistent with the second wave of the pandemic in these countries.(Figure presented)Figure 1. Global regional temporal trends in reporting of COVID-19 in patients with IBD from the SECURE-IBD registry: A. Asia, B. Europe, C. Latin America, and D. North America: March 22–28 to September 6-12 and September 13-19 to November 8–14, 2020(Figure presented)Figure 2. United States regional temporal trends in reporting of COVID-19 in patients with IBD from the SECURE-IBD registry: A. Midwest, B. Northeast, C. South, and D. West: March 22–28 to September 6-12 and September 13-19 to November 8–14, 2020
ABSTRACT
Introduction: Although several studies have reported the impact of fears relating to COVID-19 on several chronic illness populations, there are few studies focused on gastrointestinal (GI) conditions1-4. The aim was to compare how fear of COVID-19 is manifested in people living with Inflammatory Bowel Disease (IBD) compared to other GI conditions;and, how fear of COVID-19 is manifested across different demographic backgrounds (employment status, education level and country of residence) among IBD respondents using a large international sample. Aims & Methods: Participants with a GI condition (≥18years of age) were recruited from 22 countries through a web-based questionnaire. Demographic, clinical, and psychosocial information was collected in relation to the COVID-19 pandemic. An adaptation of the scale developed for IBD by Trindade & Ferreira (2020)5 measuring fear of COVID-19 (FoC;original items 1-9) and GI specific fear of COVID-19 (GI-FoC;new items 10-14) was used. Results: In 831 participants (312 IBD), there were no significant differences in FoC between IBD and other GI conditions;whilst significant increases in GI-FoC were found in IBD respondents (mean [SD]: 13.5 [5.5] vs. 10.9 [5.0], p<0.01). The greatest fears of IBD respondents were: their condition would get worse;impact on access to medical support;being at increased risk of getting COVID-19;and being at increased risk of death if they got COVID-19. Among IBD respondents, persons on sick leave had significantly more FoC than those employed (median [IQR], 31.0 [28.5-39.5] vs 26.0 [20.0-33.0], p=0.035), and significantly more GI-FoC compared to the employed (18.0 [14.5-22.0] vs 13.0 [9.0-17.0], p=0.033) or respondents outside of the labour market (12.0 [7.0-16.0], p=0.022). Persons living in a rural setting had significantly more FoC compared to persons living in regional setting (29.5 [22.0-37.8] vs 25.0 [20.0-31.3], p=0.007) and GI-FoC (15.0 [11.0-19.8] vs 12.0 [9.0-16.0], p=0.02). These persons were fearful of contracting COVID-19, having contact with someone with respiratory symptoms, having contact with healthcare professionals, going outside, meeting people, having contact with someone who was in contact with an infected person, having contact with someone infected with COVID-19, and that their IBD means being at increased risk of death if they got COVID-19. There were no differences in general FoC and GI-FoC according to educational background. However, respondents with higher education were less afraid of dying from COVID-19. Conclusion: Respondents with IBD are more afraid of the consequences of COVID-19 due to their disease compared to other GI diseases;especially, persons on sick leave or persons living in a rural setting. Persons with higher education were less afraid of dying from COVID-19. These findings should be taken into consideration to personalise the support health care providers can offer in mitigating fear related to COVID-19 in IBD patients.